文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

肌球蛋白抑制剂在转诊行室间隔减容术的梗阻性肥厚型心肌病中的应用

Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy.
PubMed 文献 · J Am Coll Cardiol · 2022-01-01

主要终点为仍符合指南标准或接受 SRT 的比例,mavacamten 组 17.9% 显著低于安慰剂组 76.8%(差 58.9%,95%CI 44.0%-73.9%,P<0.001)。

要点

  • mavacamten 治疗 16 周大幅降低符合 SRT 指南标准或接受 SRT 的患者比例
  • mavacamten 组运动后 LVOT 峰值压差平均降低 37.2 mm Hg
  • 长期免于 SRT 的获益尚待确定

核心结论

  • 在症状难以控制且符合 SRT 指南标准的 oHCM 患者中,mavacamten 治疗 16 周显著减少仍符合 SRT 标准或接受 SRT 的患者比例。
  • 长期免于 SRT 的获益尚待确定。

研究设计与样本

  • mavacamten 5 mg 每日起始,根据 LVOT 压差和 LV 射血分数滴定至 15 mg,对照安慰剂。
  • 主要终点为治疗 16 周后仍符合指南标准或接受 SRT 的复合比例。

主要发现

  • 16 周后安慰剂组 43/56(76.8%)与 mavacamten 组 10/56(17.9%)符合指南标准或接受 SRT,差异 58.9%(95%CI 44.0%-73.9%,P<0.001)。
  • 运动后 LVOT 峰值压差组间平均差异 -37.2 mm Hg,支持 mavacamten(P<0.001)。
  • NYHA 功能分级改善≥1 级者组间差异 41.1%,患者报告结局改善 9.4 分(P<0.001)。
  • NT-proBNP 与心肌肌钙蛋白 I 的组间几何均值比分别为 0.33 和 0.53(P<0.001)。

关键数值与推荐

  • 入选标准:静息或激发后 LVOT 压差≥50 mm Hg,且符合 SRT 指南标准。
  • mavacamten 剂量 5 mg 每日,按 LVOT 压差和 LV 射血分数滴定至 15 mg。

临床怎么用

  • 对于符合 SRT 指南标准且有难治症状的 oHCM 患者,mavacamten 可作为减少 SRT 需求的选择。
  • 治疗期间需根据 LVOT 压差和 LV 射血分数进行剂量滴定。

局限性

  • 长期免于 SRT 的获益尚未确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Septal reduction therapy (SRT), surgical myectomy or alcohol ablation, is recommended for obstructive hypertrophic cardiomyopathy (oHCM) patients with intractable symptoms despite maximal medical therapy, but is associated with morbidity and mortality. OBJECTIVES: This study sought to determine whether the oral myosin inhibitor mavacamten enables patients to improve sufficiently to no longer meet guideline criteria or choose to not undergo SRT. METHODS: Patients with left ventricular (LV) outflow tract (LVOT) gradient ≥50 mm Hg at rest/provocation who met guideline criteria for SRT were randomized, double blind, to mavacamten, 5 mg daily, or placebo, titrated up to 15 mg based on LVOT gradient and LV ejection fraction. The primary endpoint was the composite of the proportion of patients proceeding with SRT or who remained guideline-eligible after 16 weeks' treatment. RESULTS: One hundred and twelve oHCM patients were enrolled, mean age 60 ± 12 years, 51% men, 93% New York Heart Association (NYHA) functional class III/IV, with a mean post-exercise LVOT gradient of 84 ± 35.8 mm Hg. After 16 weeks, 43 of 56 placebo patients (76.8%) and 10 of 56 mavacamten patients (17.9%) met guideline criteria or underwent SRT, difference (58.9%; 95% CI: 44.0%-73.9%; P < 0.001). Hierarchical testing of secondary outcomes showed significant differences (P < 0.001) favoring mavacamten, mean differences in post-exercise peak LVOT gradient -37.2 mm Hg; ≥1 NYHA functional class improvement 41.1%; improvement in patient-reported outcome 9.4 points; and NT-proBNP and cardiac troponin I between-groups geometric mean ratio 0.33 and 0.53. CONCLUSIONS: In oHCM patients with intractable symptoms, mavacamten significantly reduced the fraction of patients meeting guideline criteria for SRT after 16 weeks. Long-term freedom from SRT remains to be determined. (A Study to Evaluate Mavacamten in Adults With Symptomatic Obstructive HCM Who Are Eligible for Septal Reduction Therapy [VALOR-HCM]; NCT04349072).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Desai MY, Owens A, Geske JB, et al. Myosin Inhibition in Patients With Obstructive Hypertrophic Cardiomyopathy Referred for Septal Reduction Therapy. J Am Coll Cardiol. 2022. PMID: 35798455. doi:10.1016/j.jacc.2022.04.048

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。